我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 中国知网(CNKI)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Gastro Congress 2019: Problems associated with medications taken by renal patients - Ashraf Salah Ibrahim El Ghaname - Cairo University

Ashraf Salah Ibrahim El Ghaname

From the start, we have to introduce and explain the renal disappointment tolerant and what is his condition and how these conditions are managed, as our subject really is about issues identified with dealing with the kidney quiet issues or confusions. An end stage renal disappointment understanding is a one who is enduring electrolyte awkwardness in type of: Low calcium, taking enhancements like 500 mg tablets 3 times each day and experiencing paleness taking 5 tablets of folic corrosive once day by day.
Multi nutrients for Iron, nutrient B experiencing hypertension so at any rate taking one kind of hostile to hypertensive drugs (now and again with harmful hypertension) high dosages of a few sorts of against hypertensive prescriptions are endorsed (may arrive at 230/130). Likewise, the patient on dialysis in nonstop pressure causing pressure ulcer along with uraemia causing gastritis.
The two of which suggest great administration shifting back and forth between proton siphon inhibitors and stomach settling agents to evade aluminium hydroxide defensive covering as it is not disposed of by on dialysis dynamic nutrient D (HYDROXYCALCIFEROL). For calcium digestion (assimilation and bone affidavit), different more uncommon prescriptions torment executioners for: Itching body hurts. Anti-toxins for auxiliary contaminations and catheter related diseases so when all is said in done a patient may take between 5-8 tablets multiple times day by day. That is the reason we are here to discuss.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。